Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
14 Octobre 2021 - 3:20PM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, today announced it has successfully co-developed a
novel platform of S-layer coated emulsome technology (SLET) for
next-generation drug delivery and cellular immunotherapy, together
with Professor Uwe Sleytr and the University of Natural Resources
and Life Sciences (BOKU) in Vienna, Austria.
Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO
(US63/060,235) and international PCT (US21/38327) patent
applications pertaining to the novel SLET platform.
As a vesicular nano-carrier system, emulsomes are composed of an
internal lipoidal core surrounded by phospholipid multilayers. This
emulsome nano-carrier, when loaded with bio-active agents (such as
poorly water-soluble pharmaceuticals and genetic materials,
including DNA and RNA), may increase their solubility and
bioavailability. This nano-formulation is also designed to be safe
and nontoxic. The SLET platform exploits the S-layer fusion
proteins as coating materials for the emulsome nano-carriers, in
order to provide a “molecular GPS system” to guide the trafficking
and delivery of the emulsomal payload to a targeted destination in
the body. Avalon is actively exploring the practical uses of SLET,
including targeted drug delivery, vaccine development, diagnostic
devices, and cellular therapeutic applications.
“We are very excited to announce this novel SLET platform, which
we believe will help accelerate the development of our mRNA-based
Flash-CAR™ program. The targeted delivery of mRNA to immune
effector cells by SLET could open the door to a whole new
generation of cancer immunotherapy. In addition, we see a number of
other therapeutic and diagnostic applications for this broad and
potentially transformative technology platform. Moreover, we
believe these latest patent filings will provide us robust
international IP protection for this technology and its many
potential applications,” said David Jin, M.D., Ph.D., President and
Chief Executive Officer of Avalon.
About Avalon GloboCare Corp.Avalon GloboCare
Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative immune effector cell therapy,
exosome technology, as well as COVID-19 related diagnostics and
therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth
and development, as well as competitiveness in healthcare and
CellTech industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of cellular
immunotherapy (including CAR-T/NK), exosome technology (ACTEX™),
and regenerative therapeutics. For more information about Avalon
GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments,
please follow our twitter at @avalongc_avco
Forward-Looking StatementsCertain statements
contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp.4400 Route 9, Suite 3100Freehold, NJ
07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications,
LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Avalon GloboCare (NASDAQ:AVCO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024